McKesson Corporation

NYSE:MCK Aktierapport

Börsvärde: US$99.7b

McKesson Framtida tillväxt

Future kriterier kontrolleras 2/6

McKesson förväntas öka intäkter och intäkter med 11.2% respektive 7.6% per år. EPS förväntas tillväxt med 13.7% per år. Avkastningen på eget kapital förväntas bli 102.8% om 3 år.

Viktig information

11.2%

Tillväxttakt i vinsten

13.71%

Tillväxttakt för EPS

Healthcare vinsttillväxt18.5%
Intäkternas tillväxttakt7.6%
Framtida avkastning på eget kapital102.80%
Bevakning av analytiker

Good

Senast uppdaterad28 Apr 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

McKesson - "Hold" Still Valid In 2026

May 01

MCK: Biosimilar Co Manufacturing Will Shape Future Healthcare Safe Haven Appeal

McKesson's analyst price target has been trimmed slightly, with the fair value estimate edging down by about $1 to $990.87 as analysts factor in recent target cuts alongside ongoing interest in the company's biosimilar and distribution opportunities. Analyst Commentary Recent research on McKesson has centered on how much value the market is assigning to its biosimilar pipeline, distribution scale and perceived defensiveness within healthcare, with a mix of higher and lower price targets reflecting different views on execution risk and current valuation.

MCK: Biosimilar Co Manufacturing Optionality Will Shape Future Safe Haven Appeal

McKesson's analyst-derived fair value estimate has been adjusted slightly lower, from about $997.67 to $991.67. Analysts are weighing recent trims to Street price targets and fresh caution around premium valuation against prior enthusiasm for biosimilar optionality and healthcare defensiveness.

MCK: Biosimilar And Co Manufacturing Upside Will Shape Future Safe Haven Returns

Analysts have nudged the McKesson fair value estimate slightly higher to about $998, citing a wave of Street price target increases into the $1,040 to $1,050 range and growing focus on potential upside from biosimilars and co-manufacturing. Analyst Commentary Recent Street research around McKesson clusters around two themes: valuation and execution on new growth levers such as biosimilars and co-manufacturing.

MCK: Biosimilar Optionality And Premium Safe Haven Position Will Shape Future Returns

Analysts have increased their McKesson price target from $980.40 to $995.27, citing higher Street targets that reflect new biosimilar optionality and continued interest in the stock as a perceived healthcare safe haven, even at a premium valuation. Analyst Commentary Bullish analysts are leaning into McKesson's role as a perceived healthcare safe haven and the new biosimilar angle, using these themes to justify higher valuation levels than the recent three year average.

MCK: Defensive Healthcare Premium And Buybacks Will Shape Perceived Safety Trade

Analysts have raised McKesson's fair value estimate by about $14 to $980.40, as a series of higher Street price targets, including Barclays' move to $1,050, keeps the stock in focus for investors seeking perceived safety within healthcare, even as shares trade at a premium to recent averages. Analyst Commentary Recent research has centered on McKesson's valuation after a series of price target increases, including a move to US$1,050 that highlights how closely investors are watching the name as a perceived defensive healthcare holding.

MCK: Refined Assumptions And Supportive Policy Backdrop Will Shape FY26 AOI

The McKesson analyst price target has been raised by about $24 to $966, with analysts pointing to updated fair value work, modest adjustments to the discount rate and growth assumptions, and slightly higher future P/E expectations as key drivers of the change. Analyst Commentary Recent Street research on McKesson clusters around higher price targets and refreshed valuation work, with analysts fine tuning assumptions on growth, discount rates and future P/E multiples.

MCK: North American Pharma Momentum And Supportive Policy Backdrop Will Drive FY26 AOI

Narrative Update The analyst price target for McKesson has been raised by roughly $3 to $942.00, as analysts point to steady assumptions for revenue growth, margins and P/E, along with supportive views on North American Pharma momentum, a constructive industry demand backdrop, and the absence of new onerous proposals in recent healthcare policy commentary. Analyst Commentary Recent research on McKesson is broadly constructive, with several firms lifting their price targets and pointing to supportive sector trends and company specific drivers.

MCK: North American Pharma Strength Will Support FY26 Core AOI Framework

Narrative Update: McKesson Analysts have lifted their McKesson price targets toward a range of about $900 to $1,000, citing solid North American Pharma momentum, modeled core AOI growth of around 7% for FY26, and a robust demand backdrop reflected in peers' recent results. Analyst Commentary Recent research updates reflect a more constructive stance on McKesson, with higher price targets tied to underlying business trends and peer readthroughs rather than short term trading factors.

MCK: North American Pharma Momentum Will Drive Future EPS Framework Confidence

Our McKesson narrative fair value has increased modestly to approximately $939 per share from about $935, reflecting analysts' higher price targets and conviction in sustained EPS growth, improved North American Pharma momentum, and a more robust valuation framework supported by stronger industry demand trends. Analyst Commentary Street research sentiment on McKesson remains skewed positive, with a broad wave of price target increases reflecting higher conviction in the companys ability to deliver on its upgraded long term earnings framework and FY26 guidance.

MCK: North American Pharma Momentum Will Drive Future Outlook Amid Policy Uncertainty

We modestly raise our McKesson fair value estimate to about $934.79 per share from roughly $934.71, reflecting analysts' higher price targets, stronger confidence in long term EPS growth, and sustained North American Pharma momentum. Analyst Commentary Street research on McKesson has turned increasingly constructive, with multiple firms lifting price targets in response to upgraded long term guidance, stronger segment momentum, and enhanced disclosure following the recent investor day.

MCK: Future Execution and Pharma Trends Will Shape Outlook Amid Policy Uncertainty

McKesson's analyst price target has been raised significantly, increasing by nearly $90 per share to $934.71. Analysts cite strong momentum in North American Pharma, higher long-term EPS guidance, and robust industry trends supporting continued growth.

MCK: Future Demand and Oncology Distribution Will Set the Earnings Outlook

McKesson’s analyst price target has increased from approximately $837 to $845. Analysts cite robust demand, industry-wide utilization trends, and the company’s strengthened long-term earnings outlook as key factors supporting the upward revision.

Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments

Analysts have raised their average fair value estimate for McKesson to $836.71 from $829.57. This change is attributed to increased long-term growth guidance and improved business visibility following the company’s recent investor day.

Pharmaceutical Demand And Digital Automation Will Shape Future Markets

McKesson's analyst fair value estimate has been raised from $793.21 to $829.57. This increase reflects higher price targets, driven by analysts who cite upgraded long-term growth guidance and strengthened expectations following recent investor presentations.

Pharmaceutical Demand And Digital Automation Will Shape Future Markets

McKesson’s fair value saw only a marginal increase as analyst expectations for both revenue growth and net profit margin remained virtually unchanged, with the target price moving slightly from $788.57 to $793.21. What's in the News Playhouse MD™, a pediatric healthcare brand, has entered a strategic distribution alliance with McKesson Medical-Surgical, making its products available nationwide and expanding McKesson's portfolio in pediatric care.

Why Investors Shouldn't Be Surprised By McKesson Corporation's (NYSE:MCK) P/E

Jul 07
Why Investors Shouldn't Be Surprised By McKesson Corporation's (NYSE:MCK) P/E

McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025

Mar 25

McKesson Seems Cheap, But Risks Linger

Jan 21

McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network

Nov 09

McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff

Oct 09

McKesson: The Correction Is Not Over

Sep 10

McKesson Corporation: An Interesting Health Giant With A Hidden Gem

Jul 04

Prognoser för vinst- och omsättningstillväxt

NYSE:MCK - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
3/31/2029513,2566,1666,7617,6334
3/31/2028478,1765,5086,1127,01914
3/31/2027442,4444,8925,6836,62015
3/31/2026408,5094,2674,6435,45515
12/31/2025397,9584,3409,64410,482N/A
9/30/2025387,0944,0336,0086,867N/A
6/30/2025377,5953,1645,6666,547N/A
3/31/2025359,0513,2955,2266,085N/A
12/31/2024344,5832,8261,6342,484N/A
9/30/2024330,1872,5364,3135,121N/A
6/30/2024313,7512,9593,2563,986N/A
3/31/2024308,9513,0023,6274,314N/A
12/31/2023301,5062,9982,8923,492N/A
9/30/2023291,0983,4874,3064,906N/A
6/30/2023284,0403,7554,4665,048N/A
3/31/2023276,7113,5634,6015,159N/A
12/31/2022273,9033,1464,1904,721N/A
9/30/2022272,0272,0613,9524,430N/A
6/30/2022268,4461,3964,6395,115N/A
3/31/2022263,9661,1193,8994,434N/A
12/31/2021257,0061,4154,3234,917N/A
9/30/2021250,991-4,8044,0984,753N/A
6/30/2021245,223-4,4943,2993,982N/A
3/31/2021238,228-4,5383,9014,542N/A
12/31/2020237,621-4,1895,2315,826N/A
9/30/2020234,1942,2283,9054,492N/A
6/30/2020231,0029222,8513,363N/A
3/31/2020231,0519063,8684,374N/A
12/31/2019224,945-9053,1253,615N/A
9/30/2019221,981-626N/A3,559N/A
6/30/2019217,440601N/A5,046N/A
3/31/2019214,31933N/A4,036N/A
12/31/2018213,518-319N/A3,165N/A
9/30/2018210,927113N/A3,324N/A
6/30/2018209,913-384N/A2,543N/A
3/31/2018208,35762N/A4,345N/A
12/31/2017205,4424,805N/A2,756N/A
9/30/2017201,9554,539N/A3,155N/A
6/30/2017199,8514,846N/A3,626N/A
3/31/2017198,5335,194N/A4,744N/A
12/31/2016196,4982,051N/A6,415N/A
9/30/2016194,2672,044N/A5,349N/A
6/30/2016193,0712,359N/A5,077N/A
3/31/2016190,8842,290N/A3,672N/A
12/31/2015189,1312,237N/A2,449N/A
9/30/2015187,7162,090N/A4,198N/A
6/30/2015183,1151,950N/A3,384N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: MCK s prognostiserade vinsttillväxt ( 11.2% per år) är över sparkvoten ( 3.4% ).

Resultat vs marknad: MCK s intäkter ( 11.2% per år) förväntas växa långsammare än marknaden för US ( 16% per år).

Höga tillväxtresultat: MCK s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: MCK s intäkter ( 7.6% per år) förväntas växa långsammare än marknaden för US ( 11.1% per år).

Hög tillväxtintäkter: MCK s intäkter ( 7.6% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: MCK s avkastning på eget kapital förväntas bli mycket hög om 3 år ( 102.8 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/03 01:15
Aktiekurs vid dagens slut2026/05/01 00:00
Intäkter2025/12/31
Årlig intjäning2025/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

McKesson Corporation bevakas av 33 analytiker. 15 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
David ToungArgus Research Company
Eric ColdwellBaird
Lawrence MarshBarclays